The goal of this project is to determine relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as pathology evolves from normal aging to very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNl will inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios. ADNI2 continues the currently funded AD Neuroimaging Initiative (ADNI1), a public/private collaboration between academia and industry to study biomarkers of AD as well as a recently funded Grand Opportunities grant that supplements ADNl goals and activities (GO). New aspects of ADNl include enrolling subjects with early MCI (EMCI), F18 amyloid imaging, and obtaining all clinical/cognitive, lumbar puncture CSF and plasma biomarker, and MRI/PET data on all subjects. The goals of this ADNl renewal will be accomplished by: 1) continuing annual clinical/cognitive/MRI follow up of the 476 normal controls and late MCI (LMCI) subjects previously enrolled in ADNI1;2) following the 200 EMCI subjects enrolled in the GO ADNl grant;3) additional enrollment of new healthy controls (n=150), EMCI (n=100 which adds to the 200 subjects enrolled in GO), LMCI (n=150), and AD (n=150) subjects;4) performance of F18 amyloid PET (using F18 AV-45 from AVID, Inc.) on all new subjects enrolled in ADNI2, together with FDG PET, and to obtain a 2nd F18 amyloid PET on all remaining ADNI1, GO, and ADNI2 subjects 2 years after the baseline scan;5) continue to obtain annual clinical/cognitive/blood draw/lumbar puncture for CSF, and MRI on all subjects. All collected data will be processed and analyzed by ADNl investigators including the Biostatistical Core, and made available to all qualified scientists in the world who request a password, without embargo. Hypotheses developed from current ADNl data will be replicated and new hypotheses tested, especially concerning EMCI and F18 amyloid imaging. ADNl spawned large multisite projects in other countries. No other large multisite study in the world addresses these complex issues with the sample size and statistical power of this application.

Public Health Relevance

Alzheimer's disease (AD) causes cognitive impairment and dementia in millions of Americans and costs more than $100 billion/year in the USA. This ADNl project will provide new information which will greatly facilitate design of clinical treatment trials and will help develop new diagnostic techniques which identify AD at an early stage, ultimately leading to effective treatment and prevention of AD. REVIEW OF THE OVERALL PROGRAM

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AG024904-09S5
Application #
8803060
Study Section
Program Officer
Ryan, Laurie M
Project Start
2014-09-01
Project End
2015-07-31
Budget Start
2014-09-01
Budget End
2014-07-31
Support Year
9
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Northern California Institute Research & Education
Department
Type
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94121
Zigon, Bob; Li, Huang; Yao, Xiaohui et al. (2018) GPU Accelerated Browser for Neuroimaging Genomics. Neuroinformatics 16:393-402
Wennberg, Alexandra M V; Hagen, Clinton E; Edwards, Kelly et al. (2018) Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. Int J Geriatr Psychiatry 33:1114-1120
Yan, Hao; Carmichael, Owen; Paul, Debashis et al. (2018) Estimating fiber orientation distribution from diffusion MRI with spherical needlets. Med Image Anal 46:57-72
Osadebey, Michael E; Pedersen, Marius; Arnold, Douglas L et al. (2018) Blind blur assessment of MRI images using parallel multiscale difference of Gaussian filters. Biomed Eng Online 17:76
Wei, Hongchun; Kong, Min; Zhang, Chunhua et al. (2018) The structural MRI markers and cognitive decline in prodromal Alzheimer's disease: a 2-year longitudinal study. Quant Imaging Med Surg 8:1004-1019
Wennberg, Alexandra M V; Hagen, Clinton E; Machulda, Mary M et al. (2018) The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. Neurobiol Aging 66:68-74
Huizinga, W; Poot, D H J; Vernooij, M W et al. (2018) A spatio-temporal reference model of the aging brain. Neuroimage 169:11-22
Mueller, Susanne G; Yushkevich, Paul A; Das, Sandhitsu et al. (2018) Systematic comparison of different techniques to measure hippocampal subfield volumes in ADNI2. Neuroimage Clin 17:1006-1018
Caldwell, Jessica Z K; Berg, Jody-Lynn; Shan, Guogen et al. (2018) Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume. J Alzheimers Dis 64:79-89
Estrada, Karol; Alzheimer’s Disease Neuroimaging Initiative (2018) Translating Human Genetics into Novel Drug Targets. Methods Mol Biol 1793:277-290

Showing the most recent 10 out of 1666 publications